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Inﬂammation associated cancerInterleukin-6 is a cytokine not only involved in inﬂammation and infection responses but also in the
regulation of metabolic, regenerative, and neural processes. In classic signaling, interleukin-6 stimulates target
cells via a membrane bound interleukin-6 receptor, which upon ligand binding associates with the signaling
receptor protein gp130. Gp130 dimerizes, leading to the activation of Janus kinases and subsequent
phosphorylation of tyrosine residues within the cytoplasmic portion of gp130. This leads to the engagement of
phosphatase Src homology domains containing tyrosin phosphatase-2 (SHP-2) and activation of the ras/raf/
Mitogen-activated protein (MAP) kinase (MAPK) pathway. In addition, signal transducer and activator of
transcription factors are recruited, which are phosphorylated, and consequently dimerize whereupon they
translocate into the nucleus and activate target genes. Interestingly, only few cells express membrane bound
interleukin-6 receptor whereas all cells display gp130 on the cell surface. While cells, which only express
gp130, are not responsive to interleukin-6 alone, they can respond to a complex of interleukin-6 bound to a
naturally occurring soluble form of the interleukin-6 receptor. Therefore, the generation of soluble form of the
interleukin-6 receptor dramatically enlarges the spectrum of interleukin-6 target cells. This process has been
named trans-signaling. Here, we review the involvement of both signalingmodes in the biology of interleukin-
6. It turns out that regenerative or anti-inﬂammatory activities of interleukin-6 are mediated by classic
signalingwhereas pro-inﬂammatory responses of interleukin-6 are rather mediated by trans-signaling. This is
important since therapeutic blockade of interleukin-6 by the neutralizing anti-interleukin-6 receptor
monoclonal antibody tocilizumab has recently been approved for the treatment of inﬂammatory diseases.otease; AOM, azoxymethane;
ulfate; Ig, immunoglobulin; IL,
ne bound; R, receptor; STAT,
umor necrosis factor; wt, wild
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ll rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Functional pleiotropy and redundancy are characteristic features
of cytokines, which include interleukins, interferons, colony-stimu-
lating factors, and many growth factors. Cytokines are produced by
many different cell types and often show overlapping activities
regulating proliferation or differentiation, depending on the type
and developmental state of the target cells involved. The cytokines
interleukin-6 (IL-6), IL-1, and TNFα are elevated in most, if not all,
inﬂammatory states and have been recognized as targets of
therapeutic intervention. This review will focus on the cytokine
IL-6, for which also numerous activities outside of the immune
system are known. Interestingly, it has been recognized that,although mostly regarded as a pro-inﬂammatory cytokine, IL-6
also has many regenerative or anti-inﬂammatory activities. The
molecular mechanism of how one cytokine can act in a pro- and
anti-inﬂammatory way is starting to emerge and will be discussed
in this review article.
2. IL-6 family of cytokines
Members of the interleukin 6 (IL-6) family of cytokines include IL-6,
IL-11, leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary
inhibitory factor (CNTF), cardiotropin-1 (CT-1), cardiotrophin-like
related cytokine and stimulating neurotrophin-1/B-cell stimulating
factor 3 (NNT-1), neuropoietin (NPN), IL-27, and IL-31. With the
exception of IL-31, all IL-6 type cytokines share the membrane
glycoprotein gp130 as a common receptor and signal transducer
subunit (reviewed in references 1 and 2). IL-6 and IL-11 initially bind
to the membrane bound α receptors IL-6 receptor (IL-6R) or IL-11R,
respectively. Subsequently, IL-6/IL-6R or IL-11/IL-11R complexes
associate with gp130, leading to gp130-homodimer formation and
signal initiation. Viral IL-6 (vIL-6) from the human herpes virus 8 (HHV-
8) also signals via a gp130 homodimer but without the need of theαIL-
6R [3]. LIF, CNTF, OSM, CT-1, NPN, and NNT-1 signal via gp130/LIF-R-
heterodimeric receptor complexes [4]. In addition, OSM signals via a
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to act via a gp130/WSX-1 heterodimeric receptor complex [5]. IL-31 is
the only IL-6 type cytokine that does not require the receptor chain
gp130 but instead induces the formation of a heterodimer of gp130-like
receptor (GPL) together with the OSM-R. Like IL-6 and IL-11, other IL-6
type cytokines need additional speciﬁc α receptors, including the
glycosylphosphatidylinositol (GPI)-anchored CNTF-R for CNTF, CLC,
NPN, and NNT-1 as well as the soluble Epstein–Barr-virus induced Gene
3 (EBI-3) for p28 (IL-27). CT-1 has been described to act directly via a
gp130/LIF-R heterodimer but an as yet unidentiﬁed CT-1 speciﬁc GPI-
anchored receptor may also exist on neuronal cells [6,7].
Importantly, most soluble receptor molecules are antagonists and
compete with membrane bound proteins for ligand binding, whereas
the soluble receptors sIL-6R, EBI-3, and sCNTF-R of the IL-6 family are
agonists.
3. The IL-6 receptor complex
The receptor complex mediating the biological activities of IL-6
consists of the IL-6 binding type I transmembrane glycoprotein
termed IL-6R (also designated CD126 or gp80) and the type I
transmembrane signal transducer protein gp130 (CD130). On target
cells, IL-6 ﬁrst binds to the membrane-bound non-signaling α-
receptor IL-6R (mbIL-6R). This complex of IL-6 and IL-6R then binds
to two molecules of gp130 and leads to IL-6-signal transduction,
which includes activation of JAK/STAT, ERK, and PI3K signal
transduction pathways.
IL-6 is a glycosylated protein of 21–28 kDa and has the typical
four-helix bundle structure characteristic for all IL-6-type cytokines,
made up of four long α-helices (A, B, C, D) arranged in an up-up-
down-down topology. IL-6 has three distinct receptor-binding sites
referred to as site 1 (contacting the IL-6R), site 2 (contacting gp130
between domain 2 and domain 3), and site 3 (contacting the domain 1
or Ig-like domain of gp130). Site 1 is formed by the C-terminal
residues of helix D and the C-terminal part of the AB-loop and
determines the speciﬁcity of IL-6R binding. Site 2, consisting of
residues located in the middle of helices A and C, and site 3, consisting
of residues located at the N-terminal part of the AB-loop (Site 3a) and
the C-terminal residues of the D-helix (site 3b) are needed for the
recruitment of two gp130 molecules.
In contrast to human IL-6, vIL-6 encodedby the humanherpes virus
8 (HHV-8), which shares 25% amino acid sequence homology with
human IL-6, can directly activate gp130 on cells without the
requirement of the IL-6R [3,8]. Like in human IL-6, site 2 of vIL-6
binds to the domains 2/3 of gp130 whereas site 3 of vIL-6 interacts
with Ig-like domainD1 of gp130. Interestingly, the amino acid residues
forming site 2 and site 3 showed no conservation between human IL-6
and vIL-6.
Recently, the epitopeswithin the vIL-6 protein, which enable direct
binding to gp130, were identiﬁed. Human/viral IL-6 chimeric proteins
were constructed and tested for direct binding to gp130 [9]. An IL-6
chimera, which carried both gp130 interacting sites 2 and 3 of vIL-6,
could not bind to gp130 in the absence of the IL-6R. In contrast, an IL-6
chimeric protein, containing only amino acids from site 3 of vIL-6 plus
the loop between helices B and C (named site 3c), displayed the same
functional properties as vIL-6. This human/viral IL-6 chimera could
induce STAT3 phosphorylation as well as proliferation of a cell line
dependent on IL-6 and soluble IL-6R. Since the crystal structure of vIL-6
in complex with gp130 revealed no interaction of site 3c with gp130
[8], requirement of this site for direct binding of vIL-6 to gp130 was
surprising. Interestingly, a different IL-6 chimera, consisting of site 3c of
vIL-6 alone, failed to activate gp130 in the absence of IL-6R. Therefore,
site 3c together with sites 3a and 3b appeared to be the minimal
requirement for activation of gp130 in the absence of the IL-6R [9].
The IL-6R is a glycosylated type I membrane 80 kDa protein. The
Ig-like domain of the human IL-6R is not required for binding of IL-6[10] but stabilizes the receptor during intracellular trafﬁcking through
the secretory pathway [11]. Binding of IL-6 to IL-6R is mediated by
residues on domains 2 and 3 of the IL-6R. Interestingly, murine IL-6R
lacking the Ig-domain was not able to bind IL-6 [12], pointing to a
fundamental difference between human and murine IL-6. So far, it is
unclear whether this difference explains the species speciﬁcity of
human and murine IL-6; whereas human IL-6 binds to both, human
and murine IL-6R, murine IL-6 exclusively binds to the murine IL-6R
[13]. Shedding of the IL-6R and functional role of soluble IL-6R in a
process called trans-signaling is described in Sections 4 and 5.
Gp130 is a glycosylated type I membrane protein of 130–150 kDa
with 6 extracellular domains, a single transmembrane domain, and a
cytoplasmic domain. Gp130 has an N-terminal Ig-like-domain (D1),
followed by two cytokine binding domains (CBD; domain 2 and
domain 3) and three ﬁbronectin-like (FN III)-domains (domains 4–6).
In addition to the physical interaction of gp130 and IL-6R [14], the Ig-
like domain of gp130 binds to site 3 of IL-6 and the CBM-domains of
gp130 interacting with site 2 of IL-6 [14]. The N-terminally located
CBM-domain (domain 2) contains two pairs of conserved cysteines
that form interstrand disulﬁde bonds. The C-terminally located
domain 3 contains a conserved Trp-Ser-X-Trp-Ser (WSXWS) motif
[15].
The membrane proximal domains of gp130 (domains 4–6) are
required for transmitting the signal to the cytoplasmic domain.
Deletion mutants lacking D4, D5, or D6 showed no or reduced signal
transduction activities [16]. Furthermore, a study using single-particle
electron microscopy of the symmetric IL-6/IL-6R/gp130-D1-D6
revealed that the COOH terminal portions of the cytokine binding
domain of gp130 are approximately 100 Å apart. The COOH terminal
portions of the membrane proximal ﬁbronectin III domains are in
close proximity, leading to close juxtaposition of the transmembrane
domains of the cell surface expressed receptor, enabling activation of
intracellular signaling [17]. After ligand binding, domains 4 and 5 are
orientated at an angle of approximately 80°, resulting in an acute bend
in the structure. Thus, the complete ectodomain of gp130 adopts a
wide-open “C”-shape structure [18,19].
Of importance, gp130 receptors exist as preformed, inactive
dimers at the cell membrane [20,21]. Also, the IL-6R exists as
preformed dimer at the plasma membrane [22]. Therefore, the
presumably loose and not adjusted association of the juxtamembrane
and transmembrane domain regions in the preformed dimers are not
sufﬁcient to induce signal transduction. This ﬁnding is consistent with
a cellular study in which insertion of one to four alanine residues to
the juxtamembrane intracellular region of gp130 leads to successive
impairment but not abolishment of signal transduction, indicating
that the gp130/gp130 dimer not only needs to be positioned in close
proximity but also needs to be aligned in a speciﬁc manner to allow
for full activation of the receptor [23]. Gp130 lacks intrinsic kinase
activity and it is non-covalently associated with Janus kinases (JAKs;
JAK1, JAK2, and TYK2). These tyrosine kinases become autopho-
sphorylated upon receptor engagement by IL-6 type cytokines and
subsequently phosphorylate distinct tyrosine residues within gp130
[1]. In this view, cytokine binding results in reorganization of
preformed receptor complexes in such a way that the JAKs are
rearranged and juxtaposed, allowing their activation by cross-
phosphorylation. This implies that, after ligand binding, only a subtle
reorganization within the receptor complex has to occur to initiate
intracellular signaling.
After ligand binding, the signaling complex is rapidly internalized,
mediated by dileucine-like-motifs in the cytoplasmic domain of
gp130 [24,25]. No internalization motifs have been identiﬁed within
the cytoplasmic portion of the IL-6R. Interestingly, caspase activation
by CD95L leads to degradation of the gp130 receptor chain and
thereby to blunting of IL-6 signaling [26].
Functional and structural studies suggested that IL-6 forms a
hexameric signaling complex containing two molecules of IL-6, IL-6R,
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activation model based on a tetrameric gp130 receptor complex (IL-
61/IL-6R1/gp1302) was also proposed [27]. Cotransfection of two
signaling-incompetent gp130 muteins in which one gp130 mutein
(gp130ΔD1) is unable to interact with site 2 of IL-6 and the other
gp130 mutein (gp130mutCBM) with site 3 restored IL-6 signaling,
suggesting that only one of the two IL-6 binding sites in the gp130
homodimer is sufﬁcient to induce the signaling cascade [28]. This
result is not compatible with a hexameric receptor conﬁguration.
Interestingly, the dose response curves of IL-6 and IL-11, which signal
via a homodimer of gp130, are bell-shaped, with high cytokine
concentrations leading to a decline of the biological response [29,30].
These and other results suggest that low IL-6 concentrations might
favor the formation of tetrameric IL-61/IL-6R1/gp1302 complexes
whereas higher IL-6 concentrations lead to the formation of
hexameric IL-62/IL-6R2/gp1302 complexes. Accordingly, CNTF, which
signals via a tetrameric complex of CNTF1/CNTF-R1/gp1301/LIF-R1,
and which, even at higher concentration cannot form hexameric
signaling complexes, does not show a bell-shaped dose-response over
a wide concentration range [31].
4. Generation of the soluble IL-6R
Soluble receptors have been discovered for many cytokines and
are important regulators of inﬂammatory events by acting as agonists
or antagonists of cytokine signaling. The soluble receptors of IL-1α
(sIL-1RII) and TNFα (sTNFRI and sTNFRII) inhibit the biologic activity
of their ligands and therefore act as antagonists [32–36]. In contrast,
the sIL-6R ampliﬁes IL-6-mediated signaling by activation of cell
types, which express the signal transducer protein gp130 but lack
mbIL-6R expression. Interestingly, only a few cell types express IL-6R
on the cell surface and therefore respond to IL-6 alone. Such cells are
macrophages, neutrophils, some types of T-cells and hepatocytes. In
contrast to the IL-6R, gp130 is ubiquitously expressed [37–39]. The
sIL-6R binds to IL-6 with comparable afﬁnity as the mbIL-6R and the
IL-6/sIL-6R complex acts agonistically on cells that express gp130
(Fig. 1). Activation of cells that only express gp130 via the IL-6/sIL-6R
complex is called trans-signaling whereas activation of cells via the
mbIL-6R in complex with IL-6 is called classic-signaling [33,38].
Activation of gp130 via trans-signaling is crucial for lymphocyte
trafﬁcking into the inﬂamed area by controlling chemokine expres-
sion [40,41]. Furthermore, IL-6 trans-signaling promotes T-cell
proliferation during colon cancer development and is involved in
regulating adhesion molecule expression on endothelial cells [42,43].
There are twomajormechanisms leading to generation of the sIL-6R.
The ﬁrst involves proteolytic cleavage of the mbIL-6R and is dependent
on a metalloprotease activity. The second mechanism is dependent on
the transcription of an alternative spliced IL-6R-mRNA lacking the
transmembrane and cytosolic domains [44,45]. Of note, alternative




Fig. 1. Classic- and trans-signaling of IL-6. Cells that express both gp130 and the IL-6R are resp
by the IL-6/sIL-6R complex. Activation of cells by the IL-6/sIL-6R complex is termed trans-sign
The sIL-6R binds IL-6 with comparable afﬁnity as the membrane bound form and mediatesCOOH terminal protein sequence (GSRRRGSCGL), which, however, has
no inﬂuence on the biological properties of the sIL-6R. So far, the
alternative spliced mRNA coding for the soluble form of the IL-6R has
only been described for humans but has not been identiﬁed in the
mouse, indicating that the circulating murine sIL-6R is generated
exclusively by limited proteolysis. The proteolytic cleavage of the IL-6R
is catalyzed by Zn2+-metalloproteases of the ADAM (a disintegrin and
metalloprotease) family [40,46–48]. ADAM proteases are type-I
transmembrane-proteins and are involved in limited proteolysis
(shedding) of many cytokine receptors including TNFRI+II, IL-1R, M-
CSF receptor, and IL-6R [49,50]. Among the numerous ADAM proteases
(the human genome contains 25 ADAM genes), ADAM10 and ADAM17
are themost related and sharemany substrates [51]. The IL-6R has been
described as a substrate for ADAM17 aswell as for ADAM10.Apparently,
ADAM10 is responsible for the slow constitutive IL-6R shedding,
whereas ADAM17, upon appropriate activation, causes rapid IL-6R
proteolysis [47]. ADAM17 activation and subsequent cleavage of the IL-
6R can be induced by the phorbol ester phorbol-12-myristate-13-
acetate (PMA), which is a well characterized activator of protein kinase
C (PKC) [44]. ADAM17 can also be activated by proinﬂammatory
cytokines such as IL-1β and TNFα [52], by the bacterial toxins
streptolysin O and hemolysin A [53], by cellular cholesterol depletion
[47], and by theproteosome inhibitor bortezomib [54]. In a recent study,
we identiﬁed apoptotic pathways as a physiological stimulus of IL-6R
shedding [40]. Apoptosis plays an important role in regulating growth,
tissue homeostasis, development, and immune responses. The induc-
tion of apoptosis is mediated by extrinsic and intrinsic pathways, which
require the cooperation of a series of molecules including signal
molecules and receptors, enzymes, and gene regulating proteins.
Chalaris et al. demonstrated that intrinsic and extrinsic inductions of
apoptosis by stimuli as diverse as DNA-damage, cytokine deprivation,
UV irradiation, and Fas ligation resulted in ADAM17mediated shedding
of the IL-6R from the cell surface. Apoptosis-induced shedding of the IL-
6R was caspase-dependent but PKC-, MAPK-, and ROS- independent.
Inhibition of ADAM17 during apoptosis by small pharmacological
inhibitors or by a dominant-negative ADAM17 variant resulted in
inhibition of IL-6R shedding. The sIL-6R generated during apoptosis was
biologically active and formed complexes with IL-6, resulting in IL-6
trans-signaling in non-apoptotic cells. Neutrophils have a short life span
and die rapidly via apoptosis in vivo and in vitro. Primary human
neutrophils shed the IL-6R after induction of apoptosis. Using the air
pouch mouse model of acute inﬂammation, we demonstrated that
apoptosis-induced shedding of the IL-6R by neutrophils facilitated
formation of IL-6/sIL-6R complexes, which directed IL-6 trans-signaling
on endothelial cells. These cells were hereby stimulated to secrete
chemokines leading to recruitment of mononuclear phagocytic cells
involved in the nonphlogistic removal of apoptotic neutrophils.
Furthermore, blocking IL-6 trans-signaling by neutralizing antibodies
or soluble gp130-Fcduringacute inﬂammation resulted innormal inﬂux




onsive to IL-6 (classic signaling). However, cells that express only gp130 can be activated
aling. The sIL-6R is generated by proteolytic cleavage of themembrane bound precursor.
gp130 activation in an (1) autocrine or (2) paracrine manner.
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signaling represent important steps for the resolution of inﬂammatory
responses by controlling the recruitment of mononuclear phagocytes
(Fig. 2). Thus, shedding of the IL-6R during neutrophil apoptosis may
have profound effects on the outcome of the inﬂammatory response.
In a recent study, mice with a conditional targeted IL-6R genewere
analyzed [55]. When the IL-6R gene was knocked down in
hepatocytes, the serum levels of sIL-6R went down by 32%. Ablation
of the IL-6R gene in hematopoietic cells, however, led to a reduction of
sIL-6R serum levels by 60%. From these studies, it can be concluded
that hepatocytes and hematopoietic cells are the main sources of sIL-
6R found in the circulation [55].
Interestingly, a soluble form of the signal transducer protein gp130
(sgp130) was also detected in the circulation at relatively high
concentrations (100–400 ng/ml in human plasma) [56–58]. Sgp130 is
mainly produced by alternative splicing rather than limited proteol-
ysis [59]. Since sgp130 can bind to the IL-6/sIL-6R complex in the
circulation, it acts as a speciﬁc inhibitor of IL-6 mediated trans-
signaling [60]. Classic-signaling via the mbIL-6R is not affected by
sgp130. Of note, sgp130 is speciﬁc for the IL-6/sIL-6R complex since
signaling of other IL-6-type cytokines like LIF and OSMwere inhibited
at 100–1000-fold higher concentrations and CNTF and IL-27 signaling
were not affected at all [60–62]. We developed a chimeric designer
cytokine receptor termed sgp130Fc. This fusion protein consists of the
entire extracellular portion of gp130 fused to the Fc region of human
IgG1. As sgp130Fc forms dimers, it acts as a potent inhibitor of IL-6
trans-signaling and has more than 10-fold higher inhibitory potential
compared to the monomeric natural occurring sgp130 form [60].
Sgp130Fc was used in many mouse models of human diseases and
showed highly beneﬁcial therapeutic effects in antigen-induced
arthritis, inﬂammatory bowel disease, and colon associated cancer
[42,63,64]. Moreover, it was shown that sgp130Fc blocked migration
of TH17 cells in a Staphylococcus epidermidis induced peritonitis model
[65]. Recently, we generated transgenic mice, which expressed
sgp130Fc under the control of the liver speciﬁc phosphoenol pyruvate
carboxykinase (PEPCK) promoter. The sgp130Fc protein produced in
hepatocytes and secreted in the circulation was detected at highFig. 2. Neutrophil apoptosis leads to shedding of IL-6R and to progression of the inﬂammator
IL-6, as well as a plethora of chemokines, leading to the attraction of neutrophils. Upon inﬁl
proteolytic cleavage of the membrane bound form (mIL6R). Right panel: endothelial cells
expression from CXC chemokines such as KC to CC chemokines like MCP-1, resulting mainly
mediated tethering of leukocytes is enhanced. While IL-6 induces apoptosis of neutrophi
mediated by IL-6 trans-signaling.concentrations (10–30 μg/ml). The sgp130Fc protein produced in
these mice was fully functional and efﬁciently inhibited IL-6 trans-
signaling in vivo [41]. In the air pouchmodel of acute inﬂammation, we
demonstrated that leukocyte accumulation in sgp130Fc transgenic
mice was profoundly impaired as compared to wt mice. In particular,
neutrophil and macrophage inﬁltration was disturbed at later stages
of inﬂammation, an effect which was accompanied by a reduced
production of the CC chemokine MCP-1.
In a recent study, an IL-6R neutralizing mAB, which exclusively
blocked IL-6 trans-signaling, was generated. Using this antibody, the
authors showed that intra-articular neutralization of trans-signaling
blocked local inﬂammatory responses [66]. The inhibition of collagen
induced arthritis in mice using this antibody, however, was less
effective than the inhibition by the trans-signaling inhibitor sgp130Fc,
indicating that the IL-6R neutralizing mAB was less effective [64,66].
5. Classic signaling and trans-signaling of interleukin-6
With the help of the sgp130Fc protein [60] and the fusion protein
of IL-6 and the sIL-6R named Hyper-IL-6 [67], the contribution of
classic- and trans-signaling during IL-6 mediated responses was
analyzed in numerous in vitro and in vivo studies. By comparing the
in vitro and in vivo activities of IL-6 and Hyper-IL-6, we concluded that
neural cells [68,69], neural stem cells [70], hematopoietic stem cells
[71,72], liver progenitor cells [73], and murine embryonic stem cells
[74] depend on the sIL-6R in their response to IL-6.
An important role of IL-6 in the regeneration of the liver had been
suggested by the high levels of IL-6 secreted after partial hepatectomy
[75]. Furthermore, IL-6−/− mice were shown to be impaired in liver
regeneration after 2/3 hepatectomy [76]. Experiments with IL-6
transgenic mice and IL-6/sIL-6R double transgenicmice demonstrated
that only the combination of IL-6 and sIL-6R but not IL-6 alone led to
efﬁcient hepatocellular proliferation, suggesting a decisive role of IL-6
trans-signaling in the regulation of liver regeneration [77–79]. Indeed,
we could demonstrate that the application of Hyper-IL-6, but not of IL-
6 alone, accelerated regeneration of the liver after partial hepatecto-
my [80] as well as after D-galactosamine induced liver damage [81,82].y process. Left panel: during the acute phase of inﬂammation, endothelial cells produce
tration to the site of inﬂammation, neutrophils produce soluble IL6 receptor (sIL6R) by
are subsequently stimulated via IL-6 trans-signaling, leading to a switch in chemokine
in the attraction of monocytes and T-lymphocytes. In addition, L-selectin and ICAM-1
ls and hence contributes to neutrophil clearance, maintenance of CD4+ TH17 cells is
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hepatocellular proliferation and regeneration in the liver after
chemically induced damage [83,84]. Interestingly, blocking classic
interleukin-6 signaling but not interleukin-6 trans-signaling reduced
concanavalin A-induced liver damage in mice [85].
In several models of chronic inﬂammatory bowel disease, it turned
out that sgp130Fcwas as effective as a neutralizing antibody against the
IL-6R toblock the inﬂammatoryprocess [63]. Thiswas later conﬁrmed in
a genetic model of ileitis in SAMP1/Yit mice [86]. Several mousemodels
of arthritis, namely antigen induced arthritis and collagen induced
arthritis, were analyzed and it was shown that IL-6−/− mice were
completely protected against the disease [64,87]. Interestingly, only
injection of Hyper-IL-6 but not IL-6 alonewas able to restore the disease
in antigen induced arthritis, pointing to an involvement of trans-
signaling in the development of this autoimmune disease [87]. The
application of sgp130Fc completely blocked the development of
arthritis in both animal models [64,87], underlining the importance of
IL-6 trans-signaling. We could also show that, in a murine peritonitis
model, which depended on the injection of sterile supernatants of
Staphylococcus epidermidis, the progression from the neutrophilic to the
mononuclear stage depended on IL-6 trans-signaling. This progression
could be induced by the injection of Hyper-IL-6 and could be blocked by
the application of sgp130Fc [88]. The induction of inﬂammatory colon
cancer in the AOM/DSS model could be blocked to the same degree by
the application of a neutralizing antibody against the IL-6R and by
sgp130Fc, again demonstrating that the development of inﬂammation
induced cancer depended on IL-6 trans-signaling [42]. These results
were recently conﬁrmed in a mouse model of colitis-associated cancer,
in which mice were treated over 9 cycles with DSS without prior
treatment with the mutagen AOM [89].
In patients with malignant ovarian cancer IL-6 trans-signaling on
endothelial cells prevented chemotherapy-induced apoptosis, in-
duced endothelial hyperpermeability, and increased transendothelial
migration of ovarian cancer cells. Selective targeting of IL-6 trans-
signaling in mice strongly reduced ascites formation in a xenograft
model [90].
Interestingly, in a recent report, itwas shownthat IL-6−/−miceupon
DSS treatment showed a higher inﬂammatory score than wt mice. This
was explained by the positive effect of IL-6 on the regeneration of
intestinal epithelial cells upon wounding brought about by the
application of the irritant DSS [91]. A regenerative effect of IL-6 was
already demonstrated in earlier studies with the enteric bacterial
pathogen Citrobacter rodentium [92]. The importance of the regenera-
tion of intestinal epithelial cells after DSS treatment was recently
underlined by a studyusingmice,which expressed extremely low levels
of the protease ADAM17, the enzyme known to be responsible for the
cleavage of TNFα, IL-6R, and ligands of the EGF-R. In the absence of
ADAM17 activity, the lack of EGF-R activity led to the complete absence
of STAT3 phosphorylation and consequently of regenerative prolifera-
tion in the epithelium of the gut. Accordingly, a breakdown of the
intestinal barrier and inﬁltration of immune cells was observed, which
led to severe weight loss and death of mice [93].
In murine sepsis models, blockade of IL-6 trans-signaling was
sufﬁcient to rescue the mice from death [94,95]. Interestingly, in the
caecumpuncture ligationmodel, global IL-6 blockadewas less beneﬁcial
than selective blockade of IL-6 trans-signaling with the sgp130Fc
protein. This could be explained by the fact that sgp130Fc only blocks
IL-6 bound to the sIL-6R. Since during sepsis, the levels of IL-6markedly
exceed the levels of sIL-6R, enough IL-6 is left activewhich can stimulate
regenerative proliferation in the epithelium of the gut, whereas in the
case of global IL-6 blockade, no active IL-6 is left [94].
These examples not only clearly demonstrated that the pro-
inﬂammatory activities of IL-6 were dependent on trans-signaling.
They also showed that IL-6 has regenerative activities, which, when
absent, aggravated the development of the inﬂammatory process.
Since intestinal epithelial cells express the mbIL-6R, it can beconcluded that these regenerative (or anti-inﬂammatory) activities
of IL-6 most likely depended on classic-signaling via the mbIL-6R [42].
6. Constitutive activation of gp130 by ligand
independent dimerization
Besides the ligand-dependent activation of gp130 by IL-6 type
cytokines, it can also be activated in a ligand-independentwayby forced
dimerization. Replacement of the entire extracellular domains of gp130
with the leucine zipper region of the c-jun protein created the chimeric
receptor protein L-gp130 [96]. Upon retroviral transduction into an IL-3
and/or IL-6-dependent pre B-cell line, STAT3 as well as ERK1/2
phosphorylation was detected and the cells exhibited ligand-indepen-
dent growth over several months. Furthermore, transfection of murine
embryonal stem cells with L-gp130 led to up-regulation of the stem cell
factor OCT-4 and thus suppression of differentiation [96].
In 2009, Rebouissou et al. described naturally occurring, ligand-
independent, and constitutively active gain-of-function gp130 variants
in inﬂammatory hepatocellular adenomas in humans. These variants
had in-frame deletions in the domain 2 of gp130 (contacting site 2 of IL-
6) resulting in a marked ligand-independent activation of the gp130
signaling pathway in inﬂammatory hepatocellular adenomas. The gain-
of-function gp130 mutations in these human hepatocellular adenomas
were linked to the activation of the acute inﬂammatory phase observed
in malignant conversion of hepatocytes [97]. Interestingly, we had
already observed liver adenoma formation in IL-6/sIL-6R double
transgenic mice but not in IL-6 single transgenic mice [98], indicating
that this process was induced by IL-6 trans-signaling.
Recently, Suthaus et al. showed that gp130 could also be activated
in a rather different way of ligand-independent dimerization [99]. To
achieve ligand-independent dimerization of homo- and heterodi-
meric gp130-type receptor complexes including gp130/gp130,
gp130/LIFR, gp130/OSM-R, gp130/WSX-1, and OSM-R/GPL, a novel
system based on IL-15/IL-15R-sushi domain was established, in which
the entire extracellular domains of gp130 and other gp130-type
receptors were replaced by IL-15 or the IL-15R. IL-15 binds with high
afﬁnity to the IL-15R [100]. A chimeric IL-15-gp130 receptor again led
to receptor phosphorylation, subsequent STAT1/3 and ERK1/2
phosphorylation, and cytokine-independent growth of a factor-
dependent pre B-cell line [99] which might be explained by the
tendency of IL-15 to form dimers and multimers (Inken Lorenzen,
personal communication [101]). However, fusion of IL-15 to truncated
receptors including LIFR, OSM-R, WSX-1, and GPL did not show
ligand-independent activation of the respective homodimeric recep-
tor, although other reports showed that functional homodimerization
of LIFR, OSMR, and GPL could be achieved by artiﬁcial ligand-induced
systems [102,103]. Functional ligand-independent heterodimeriza-
tion of gp130/LIFR, gp130/OSMR, gp130/WSX-1, and OSMR/GPL
receptor complexes was achieved by co-expression of IL-15-LIFR, IL-
15-OSMR, or IL-15-WSX-1 with IL-15R domain fused to gp130 (N-
terminally truncated) or GPL (N-terminally truncated) and led to
cytokine-independent growth of the respective factor-dependent pre
B-cell lines [99]. In addition, functional homodimerization of LIFR/LIFR
and GPL/GPL could be achieved by co-expression of IL-15-LIFRwith IL-
15R-sushi-LIFR and IL-15-GPL with IL-15R-sushi-GPL (unpublished
data). It remains open whether such heterodimeric complexes will
also be found in vivo as recently exempliﬁed for the constitutive,
ligand-independent somatic in-frame deletion variants of gp130 [97].
7. Activities of interleukin-6 in vivo
7.1. Interleukin-6 as an activator of the immune system
There are several lines of evidence suggesting that IL-6 plays a
pivotal role during the transition from innate to acquired immunity.
Acute inﬂammation is characterized by an initial inﬁltration of
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48 h in order to prevent increased tissue damage from the
accumulation of neutrophil-secreted proteases and reactive oxygen-
species at the site of inﬂammation. Endothelial cells as well as other
vascular elements that are activated by microbial products, IL-1β or
TNFα, produce various chemokines together with IL-6, leading to the
attraction of neutrophils in the initial phase. Proteolytic processing of
the IL-6R from invading neutrophils subsequently drives IL-6 trans-
signaling in resident tissue cells, leading to a switch from neutrophil to
monocyte recruitment by suppressing mainly neutrophil-attracting
(CXCL1/Groα, CXCL8/IL-8, CX3CL1/fractalkine) and enhancing mainly
monocyte-attracting chemokines (CCL2/MCP-1, CCL8/MCP-2, CXCL5/
ENA-78, CXCL6/GCP-2) [88,104–106]. Moreover, cell adhesion mole-
cules like ICAM-1, VCAM-1, and CD62E (E-selectin) on endothelial
cells, as well as L-selectin (CD62L) on lymphocytes are upregulated by
IL-6 trans-signaling, thereby enhancing leukocyte transmigration
[43,105,107]. Besides its role in attracting monocytes, IL-6 trans-
signaling has been shown to skew monocyte differentiation towards
macrophages by upregulating M-CSF receptor expression [108].
Studies in signaling defective gp130 knock-in mice suggest that the
level of M-CSFR expression is directly related to the extent of ERK
activation, as overactivation of STAT3 suppressed M-CSFR expression
[109]. The ﬁnding that IL-6 induces neutrophil apoptosis further
supports the notion that IL-6 substantially contributes to the
resolution of acute neutrophil inﬁltration [105].
Analysis of peritoneal inﬂammation in IL-6−/− mice revealed that
IL-6 is necessary for T cell recruitment. IL-6 trans-signaling triggers the
expression of T cell attracting chemokines (CCL4, CCL5, CCL17, and
CXCL10), a process which could be blocked by sgp130Fc [110].
Moreover, IL-6 has been shown to rescue T cells from entering
apoptosis, a process that seems to rely on STAT3-dependent
upregulation of anti-apoptotic regulators (Bcl-2, Bcl-xL) and modu-
lation of Fas surface expression [63,104,111].
Besides its role in the recruitment and anti-apoptosis of T lympho-
cytes, IL-6 plays a crucial role in B and T cell differentiation. IL-6 was
initially characterized as a factor that enhances antibody production in a
B cell line [112] and supports growth of B lineage neoplasms [31,113].
Likewise, IL-6−/− mice have an impaired IgG production upon
immunization with a T cell-dependent antigen [114]. More recently, it
has been shown that IL-6 promotes B cell helper capabilities of CD4+ T
cells through increased IL-21 production [115,116].
Upon activation by antigen-presenting cells, naïve T-helper
precursors can differentiate into TH1, TH2, or TH17 and regulatory T
(Treg) cells. IL-6 has been shown to skew T cell differentiation towards
TH2 and TH17. TH2 cell differentiation is thereby governed by inducing
the expression of IL-4 via upregulation of NFATc2 and by the
suppression of IFNγ signaling via upregulation of SOCS1 [117,118].
Recently, it has been shown that IL-6 can strongly inhibit the TGFβ-
mediated differentiation of naïve CD4+ T-cells into regulatory T-cells
(Treg), which inhibit autoimmunity and protect against tissue injury.
On the other hand, the combination of TGFβ and IL-6 induced the
formation of IL-17 secreting TH17 cells, a subset of T helper cells,
distinct from TH1 and TH2 cells that are implicated in the induction of
autoimmune diseases [119,120]. Interestingly, it was shown that only
the combination of IL-6/sIL-6R but not IL-6 alone led to the efﬁcient
suppression of Treg cells and the induction of TH17 cells, indicating
that IL-6 trans-signaling plays an important role in T-cell differenti-
ation [121].
Interestingly, TGFβ enhanced IL-6 induced STAT3 phosphorylation
by lowering the expression of SOCS3. In vitro, suppression of SOCS3 in
naïve T cells enhanced IL-6 induced RORγt expression albeit to a lesser
extent than when cells were stimulated with IL-6 and TGFβ [122].
These data support the notion that persistent STAT3 activation is
needed to reverse the Foxp3-mediated repression of RORγt and RORα
and thereby the differentiation and maintenance of TH17 cells. In line
with this is the ﬁnding that an IL-21 autocrine loop, which also leadsto STAT3 activation, is established during the course of TH17
differentiation. The induction of pathogenic TH17 cell formation can
also be induced by IL-6 in concert with IL-1β and IL-23. In these
settings, IL-6 is important to upregulate the IL-23 receptor in naïve
CD4+ T-cells via a STAT3-dependent pathway [123].
Interestingly, whereas naïve T cells in the periphery express mbIL-
6R, IL-6R is proteolytically shed from activated T cells. Therefore,
differentiation of TH17 cells is mediated via IL-6 classic-signaling
whereas the maintenance of activated TH17 cells has been shown to
be strongly supported by IL-6 trans-signaling [65]. Together, these data
suggest that, in the absence of any inﬂammatory insult, TGFβ suppresses
the generation of effector T cells and induces Treg cells. However, during
inﬂammation or infection, IL-6 with the help of sIL-6R suppresses Treg
development and favors the differentiation of effector TH17 cells (Fig. 3).
This is in accordance with the ﬁndings that IL-6−/−mice are protected
from experimental autoimmune encephalomyelitis.
7.2. Interleukin-6 and metabolic control
A role of IL-6 in the control ofmetabolismhas been suspected based
on several observations. The group of Pedersen found thatmuscle cells
upon exercise secreted large amounts of IL-6 [124,125]. On the other
hand, it was seen that adipocytes of obese individuals secrete IL-6, an
activity which correlated with the adipocyte volume [126]. Therefore,
obesity was regarded as a state of chronic, low-grade inﬂammation
[127]. Strikingly, IL-6−/− mice were found to develop late onset
obesity [128], although this ﬁnding could not be reproduced by other
authors [129]. In a recent study, carefully comparing wt and IL-6−/−
mice, it was demonstrated that mice in the absence of IL-6 develop
glucose intolerance and insulin resistance. Furthermore, IL-6−/−mice
exhibited signs of liver inﬂammation [130]. When the IL-6R gene was
deleted only in hepatocytes, mice developed a reduction in insulin
sensitivity and glucose tolerance [131]. Interestingly, these mice also
developed liver inﬂammation, which could be blocked upon blockade
of TNFα, suggesting a pivotal balance of IL-6 and TNFα signaling in the
liver [131].
Of note, in patients receiving the IL-6R neutralizing mAb Actemra
(tocilizumab), an increase in body weight of approximately 4 kg (7%)
and marked hypertriglyceridemia and hypercholsterinemia during
the treatment period was detected, implying a link between blockade
of IL-6 signaling and impairedmetabolic homeostasis in humans [132]
These ﬁndings are reminiscent with the unexpected weight lowering
effects of CNTF in clinical trials with patients suffering from motor
neuron diseases [133]. Moreover, transgenic mice overexpressing IL-6
and sIL-6R, which showed massive stimulation of gp130 signaling
pathway, were signiﬁcantly smaller than wt mice and did not develop
visible fat pads [78]. Given the mentioned results with mice lacking
the hepatic IL-6R, and since hepatocytes express membrane bound IL-
6R, it can be suspected that the effect of IL-6 on hepatic control of
insulin sensitivity and glucose tolerance is mediated by IL-6 classic-
rather than by trans-signaling [134]. It will therefore be interesting to
see whether speciﬁc blockade of IL-6 trans-signaling by sgp130Fc will
have an effect on insulin sensitivity and glucose tolerance.
7.3. Interleukin-6 and bone metabolism
Bone homeostasis is regulated by the balance of osteoblasts, which
are building up bone and osteoclasts, which degrade bone. It was
shown that osteoclast formation was triggered by IL-6 only in the
presence of sIL-6R [135]. The importance of IL-6 was underlined by
experiments with IL-6−/− mice, which were completely protected
from bone loss after ovariectomy, which is a model for bone loss in
females after menopause [136].
RANK ligand (RANKL) is an essential factor for osteoclastogenesis
since it stimulates differentiation of myeloid precursor cells into
osteoclasts by binding to its signaling receptor, RANK [137]. RANKL
Fig. 3. Role of IL-6 in T-cell differentiation. Activation of STAT3 plays a central role during the development of TH2 and TH17 cells. Left panel: TGFβ alone induces the differentiation of
naïve CD4+ T-cells into regulatory T-cells (Treg). TGFβ in combination with IL-6 triggers the differentiation of naïve T-cells towards TH17 cells. TGFβ thereby enhances P-STAT3 levels
via suppression of SOCS3. Differentiated TH17 cells sustain elevated P-STAT3 levels either via gp130 trans-signaling or via an autocrine IL-21 loop. Right panel: IL-6 induces STAT3
activation in naïve T-cells. Consequently, IL-4 production as well as inhibition of IFNγ signaling via upregulated SOCS1 shifts the balance towards TH2 formation.
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via the JAK/STAT signaling pathway [137]. Accordingly, it was shown
that neutralizing anti-IL-6 mAbs inhibited osteoclast formation.
Interestingly, IL-6 levels and certain IL-6 gene polymorphisms have
been associated with bone mineral density alterations in inﬂamma-
tory disease [138]. Taken together, these data show that IL-6, most
likely via IL-6 trans-signaling, plays an important role in the regulation
of bone homeostasis.
7.4. Interleukin-6 and pain
It was shown that IL-6 in combination with sIL-6R sensitized rat
skin nociceptors to heat in vivo and that heat-activated ionic currentActivation of STAT3 leading to:
•Intestinal epithelial cell proliferation
•Inhibition of epithelial cell apoptosis
Fig. 4. Pro- and anti-inﬂammatory properties of IL-6. IL-6 is a pleiotropic cytokine with pro- a
signalingmediates the activation of anti-inﬂammatory pathways on target cells. In a murine c
signaling pathways which induce the regeneration of intestinal epithelial cells after DSS i
disorders like Crohn's disease and rheumatoid arthritis. Trans-signaling leads to activation
signaling on T-cells leads to inhibition of apoptosis, inhibition of Treg differentiation, and diwas modulated by IL-6 in rat sensory neurons [139,140]. Subsequent-
ly, using mice lacking gp130 in peripheral sensory neurons, it was
demonstrated that IL-6/gp130 ligand-receptor complex induced heat
hypersensitivity both in vitro and in vivo. This process was mediated
by activation of PKC-δ via Gab1/2/PI3K and subsequent regulation of
TRPV1, a member of the transient receptor potential (TRP) family of
ion channels [141]. A key role for IL-6 signaling in pathological pain
was conﬁrmed using IL-6−/− mice. These mice failed to develop
thermal hyperalgesia [142]. This effect of IL-6 is most likely mediated
via IL-6 trans-signaling via the soluble IL-6R since sgp130Fc transgenic
mice [41] reacted signiﬁcantly slower than wt mice upon exposure to
heat in a hot plate assay (PC Baier, T Schiffelholz, S Rose-John, J
Scheller, unpublished results).Activation of the immune system:
•Recruitment of mononuclear cells
•Inhibition of T-cell apoptosis
•Inhibition of Treg differentiation
nd anti-inﬂammatory properties. In several mousemodels, it was shown that IL-6 classic
olon cancer model, IL-6 classic signaling is essential for the activation of STAT3-mediated
nduced damage. In contrast, IL-6 trans-signaling is observed in chronic inﬂammatory
of the immune system by the recruitment of monocytes to the inﬂamed area. Trans-
fferentiation of TH17 cells.
885J. Scheller et al. / Biochimica et Biophysica Acta 1813 (2011) 878–888These results demonstrate that beneﬁcial results can be expected
in patients upon administration of IL-6 neutralizing agents such as the
IL-6R neutralizing mAb Actemra (tocilizumab), which has recently
been approved for treatment of rheumatoid arthritis patients in
Europe and in the United States.
8. Perspectives and conclusions
IL-6 is involved not only in the activation of the immune system
but also in regenerative processes as well as in the regulation of
metabolism, in the maintenance of bone homeostasis, and in many
neural functions. It turned out that, in all cases tested, pro-
inﬂammatory functions of IL-6 could be inhibited by sgp130Fc,
which does not affect IL-6 responses via the mbIL-6R. On the other
hand, functions of IL-6 such as metabolic control in the liver and
regeneration of the epithelium in the intestine seem to be mediated
via the mbIL-6R (Fig. 4). This view bears important consequences on
the therapeutic blockade of IL-6 as a treatment of chronic inﬂamma-
tory diseases. Patients with such diseases need to be treated for many
years if not for their entire life span. In view of the complex biology of
IL-6, long-term global blockade of this cytokine should be carefully
considered.Whereas most IL-6 blocking agents block both classic- and
trans-signaling, speciﬁc trans-signaling blockade is under development
[143].
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